484 related articles for article (PubMed ID: 17651170)
1. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
Esfandiarpour I; Dabiri SH
Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
Momeni AZ; Aminjavaheri M
Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol in the treatment of American cutaneous leishmaniasis.
Martinez S; Marr JJ
N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
[TBL] [Abstract][Full Text] [Related]
4. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
5. Treatment of recurrent cutaneous Leishmaniasis.
Momeni AZ; Aminjavaheri M
Int J Dermatol; 1995 Feb; 34(2):129-33. PubMed ID: 7737774
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
Sadeghian G; Nilfroushzadeh MA; Iraji F
Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
[TBL] [Abstract][Full Text] [Related]
7. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
Salmanpour R; Handjani F; Nouhpisheh MK
J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Munir A; Janjua SA; Hussain I
Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
Momeni AZ; Reiszadae MR; Aminjavaheri M
Int J Dermatol; 2002 Jul; 41(7):441-3. PubMed ID: 12121563
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A
Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis.
Kashani MN; Firooz A; Eskandari SE; Ghoorchi MH; Khamesipour A; Khatami A; Javadi A; Dowlati Y
Eur J Dermatol; 2007; 17(6):513-5. PubMed ID: 17951131
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
[TBL] [Abstract][Full Text] [Related]
15. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol.
Manna L; Reale S; Vitale F; Picillo E; Pavone LM; Gravino AE
Vet J; 2008 Aug; 177(2):279-82. PubMed ID: 17553711
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Esfandiarpour I; Farajzadeh S; Rahnama Z; Fathabadi EA; Heshmatkhah A
Int J Dermatol; 2012 Oct; 51(10):1221-5. PubMed ID: 22994669
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Esfandiarpour I; Alavi A
Int J Dermatol; 2002 Aug; 41(8):521-4. PubMed ID: 12207774
[TBL] [Abstract][Full Text] [Related]
18. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
[TBL] [Abstract][Full Text] [Related]
19. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
Torres M; BardagĂ M; Roura X; Zanna G; Ravera I; Ferrer L
Vet J; 2011 Jun; 188(3):346-51. PubMed ID: 20594876
[TBL] [Abstract][Full Text] [Related]
20. Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006.
Sharifi I; Fekri AR; Aflatoonian MR; Khamesipour A; Mahboudi F; Dowlati Y; Nadim A; Modabber F
Int J Dermatol; 2010 May; 49(5):557-61. PubMed ID: 20534092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]